

# Glenn W Kaatz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103893/publications.pdf>

Version: 2024-02-01

101  
papers

6,030  
citations

44069

48  
h-index

76900

74  
g-index

102  
all docs

102  
docs citations

102  
times ranked

4950  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibacterial and resistance modifying activity of. <i>Phytochemistry</i> , 2004, 65, 3249-3254.	2.9	309
2	Multidrug Resistance in <i>Staphylococcus aureus</i> Due to Overexpression of a Novel Multidrug and Toxin Extrusion (MATE) Transport Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1857-1864.	3.2	241
3	A novel inhibitor of multidrug efflux pumps in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 13-17.	3.0	186
4	Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 719-726.	3.2	184
5	Efflux-Related Resistance to Norfloxacin, Dyes, and Biocides in Bloodstream Isolates of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3235-3239.	3.2	179
6	Multidrug efflux pumps of Gram-positive bacteria. <i>Drug Resistance Updates</i> , 2016, 27, 1-13.	14.4	171
7	Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline. <i>Clinical Therapeutics</i> , 2014, 36, 1317-1333.	2.5	151
8	Mechanisms of fluoroquinolone resistance in genetically related strains of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2733-2737.	3.2	137
9	Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperzolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against <i>Staphylococcus aureus</i> , Coagulase-Negative Staphylococci, <i>Enterococcus faecalis</i> , and <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 721-724.	3.2	132
10	Evidence for the Existence of a Multidrug Efflux Transporter Distinct from NorA in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1404-1406.	3.2	125
11	Antibacterials and modulators of bacterial resistance from the immature cones of <i>Chamaecyparis lawsoniana</i> . <i>Phytochemistry</i> , 2007, 68, 210-217.	2.9	121
12	Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 335-340.	3.2	117
13	Multidrug efflux pump overexpression in <i>Staphylococcus aureus</i> after single and multiple in vitro exposures to biocides and dyes. <i>Microbiology (United Kingdom)</i> , 2008, 154, 3144-3153.	1.8	107
14	From Phenothiazine to 3-Phenyl-1,4-benzothiazine Derivatives as Inhibitors of the <i>Staphylococcus aureus</i> NorA Multidrug Efflux Pump. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4321-4330.	6.4	105
15	The Phenolic Diterpene Totarol Inhibits Multidrug Efflux Pump Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4480-4483.	3.2	103
16	Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the <i>S. aureus</i> NorA Efflux Pump. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5722-5736.	6.4	102
17	Characteristics of Patients With Healthcare-Associated Infection Due to SCCmecType IV Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 1025-1031.	1.8	100
18	Polyacylated Oligosaccharides from Medicinal Mexican Morning Glory Species as Antibacterials and Inhibitors of Multidrug Resistance in <i>Staphylococcus aureus</i> . <i>Journal of Natural Products</i> , 2006, 69, 406-409.	3.0	99

#	ARTICLE	IF	CITATIONS
19	Catechin Gallates Inhibit Multidrug Resistance (MDR) in <i>Staphylococcus aureus</i> . <i>Planta Medica</i> , 2004, 70, 1240-1242.	1.3	97
20	Community- and health care-associated methicillin-resistant <i>Staphylococcus aureus</i> : a comparison of molecular epidemiology and antimicrobial activities of various agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 41-47.	1.8	94
21	Inhibition of drug efflux pumps in <i>Staphylococcus aureus</i> : current status of potentiating existing antibiotics. <i>Future Microbiology</i> , 2013, 8, 491-507.	2.0	94
22	Ethidium Bromide MIC Screening for Enhanced Efflux Pump Gene Expression or Efflux Activity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5070-5073.	3.2	84
23	The emergence of resistance to ciprofloxacin during treatment of experimental <i>Staphylococcus aureus</i> endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 1987, 20, 753-758.	3.0	83
24	Pyrazolo[4,3- <i>c</i> ][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3568-3572.	6.4	82
25	N-Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1755-1758.	2.2	81
26	Daptomycin Activity against <i>Staphylococcus aureus</i> following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 831-836.	3.2	80
27	Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 254-261.	2.5	79
28	Effect of Promoter Region Mutations and <i>mgrA</i> Overexpression on Transcription of <i>norA</i> , Which Encodes a <i>Staphylococcus aureus</i> Multidrug Efflux Transporter. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 161-169.	3.2	79
29	Inhibitors of Bacterial Multidrug Efflux Pumps from the Resin Glycosides of <i>Ipomoea murucoides</i> . <i>Journal of Natural Products</i> , 2008, 71, 1037-1045.	3.0	79
30	Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2109-2112.	2.2	78
31	MepR, a Repressor of the <i>Staphylococcus aureus</i> MATE Family Multidrug Efflux Pump MepA, Is a Substrate-Responsive Regulatory Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1276-1281.	3.2	76
32	Mechanisms of daptomycin resistance in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 280-287.	2.5	75
33	Goldenseal ( <i>Hydrastis canadensis</i> L.) Extracts Synergistically Enhance the Antibacterial Activity of Berberine via Efflux Pump Inhibition. <i>Planta Medica</i> , 2011, 77, 835-840.	1.3	74
34	Evaluation of daptomycin treatment of <i>Staphylococcus aureus</i> bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 334-340.	3.0	71
35	Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 204-209.	2.5	69
36	Discovery of Novel Inhibitors of the NorA Multidrug Transporter of <i>Staphylococcus aureus</i> . <i>Journal of Medicinal Chemistry</i> , 2011, 54, 354-365.	6.4	67

#	ARTICLE	IF	CITATIONS
37	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 2453-2463.	5.5	66
38	Indole Based Weapons to Fight Antibiotic Resistance: A Structure-Activity Relationship Study. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 867-891.	6.4	64
39	A new plant-derived antibacterial is an inhibitor of efflux pumps in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 513-518.	2.5	62
40	Efficacy of LY333328 against Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 981-983.	3.2	60
41	Pharmacophore-Based Repositioning of Approved Drugs as Novel <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1598-1604.	6.4	59
42	Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against <i>Streptococcus pneumoniae</i> in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2606-2614.	3.2	57
43	Identification and characterization of a novel efflux-related multidrug resistance phenotype in <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 833-838.	3.0	56
44	Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate <i>Staphylococcus aureus</i> and Vancomycin-Intermediate Methicillin-Resistant <i>S. aureus</i> Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the "Seesaw Effect". <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2664-2668.	3.2	54
45	A Mass Spectrometry-Based Assay for Improved Quantitative Measurements of Efflux Pump Inhibition. <i>PLoS ONE</i> , 2015, 10, e0124814.	2.5	53
46	Structural and biochemical characterization of MepR, a multidrug binding transcription regulator of the <i>Staphylococcus aureus</i> multidrug efflux pump MepA. <i>Nucleic Acids Research</i> , 2009, 37, 1211-1224.	14.5	52
47	Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1745-1749.	2.2	51
48	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4975-4989.	6.4	51
49	Mechanisms of in-vitro-selected daptomycin-non-susceptibility in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 442-446.	2.5	49
50	2-Phenylquinoline <i>S. aureus</i> NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7827-7848.	6.4	46
51	Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1654-1659.	3.2	44
52	In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against <i>Staphylococcus aureus</i> in a pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 150-160.	2.5	42
53	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 881-885.	2.2	41
54	From 6-Aminoquinolone Antibacterials to 6-Amino-7-thiopyranopyridinylquinolone Ethyl Esters as Inhibitors of <i>Staphylococcus aureus</i> Multidrug Efflux Pumps. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4466-4480.	6.4	41

#	ARTICLE	IF	CITATIONS
55	Alternative Mutational Pathways to Intermediate Resistance to Vancomycin in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Infectious Diseases</i> , 2013, 208, 67-74.	4.0	39
56	Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1921-1924.	3.2	38
57	Synthesis and evaluation of PSSRI-based inhibitors of <i>Staphylococcus aureus</i> multidrug efflux pumps. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1368-1373.	2.2	38
58	Inhibition of the NorA multi-drug transporter by oxygenated monoterpenes. <i>Microbial Pathogenesis</i> , 2016, 99, 173-177.	2.9	36
59	Structural mechanism of transcription regulation of the <i>Staphylococcus aureus</i> multidrug efflux operon <i>mepRA</i> by the MarR family repressor MepR. <i>Nucleic Acids Research</i> , 2014, 42, 2774-2788.	14.5	35
60	Analyses of Multidrug Efflux Pump-Like Proteins Encoded on the <i>Staphylococcus aureus</i> Chromosome. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 747-748.	3.2	34
61	Improved Potency of Indole-Based NorA Efflux Pump Inhibitors: From Serendipity toward Rational Design and Development. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 517-523.	6.4	33
62	The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of <i>Staphylococcus aureus</i> in an in-vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 343-349.	3.0	32
63	Bacterial efflux pump inhibition. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 191-8.	2.3	32
64	Introduction of a <i>norA</i> Promoter Region Mutation into the Chromosome of a Fluoroquinolone-Susceptible Strain of <i>Staphylococcus aureus</i> Using Plasmid Integration. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2222-2224.	3.2	30
65	Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> : Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1315-1320.	3.2	29
66	Correlation of vancomycin and daptomycin susceptibility in <i>Staphylococcus aureus</i> in reference to accessory gene regulator ( <i>agr</i> ) polymorphism and function. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1190-1193.	3.0	29
67	Antimicrobial Susceptibility and Staphylococcal Chromosomal CassettemecType in Community- and Hospital-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2007, 27, 3-10.	2.6	29
68	Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 805-807.	3.2	29
69	Inability of a reserpine-based screen to identify strains overexpressing efflux pump genes in clinical isolates of <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 360-363.	2.5	29
70	Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 223-233.	2.4	28
71	Searching for Novel Inhibitors of the <i>S. aureus</i> NorA Efflux Pump: Synthesis and Biological Evaluation of the 1,4-benzothiazine Analogues. <i>ChemMedChem</i> , 2017, 12, 1293-1302.	3.2	28
72	Mutagenesis and Modeling To Predict Structural and Functional Characteristics of the <i>Staphylococcus aureus</i> MepA Multidrug Efflux Pump. <i>Journal of Bacteriology</i> , 2013, 195, 523-533.	2.2	27

#	ARTICLE	IF	CITATIONS
73	Characterizing Vancomycin-Resistant Enterococcus Strains with Various Mechanisms of Daptomycin Resistance Developed in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4748-4754.	3.2	21
74	Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 254-256.	3.2	21
75	Effect of substrate exposure and other growth condition manipulations on norA expression. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 364-369.	3.0	20
76	Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3093-3097.	2.2	20
77	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and <i>S. aureus</i> NorA. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 248-251.	2.8	20
78	Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. <i>MedChemComm</i> , 2012, 3, 1092.	3.4	20
79	Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 119-125.	1.8	19
80	Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1305-1310.	3.0	19
81	The Molecular Mechanisms of Allosteric Mutations Impairing MepR Repressor Function in Multidrug-Resistant Strains of Staphylococcus aureus. <i>MBio</i> , 2013, 4, e00528-13.	4.1	19
82	Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 428-433.	5.5	19
83	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant Staphylococcus aureus. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 25-29.	2.5	18
84	Functional Consequences of Substitution Mutations in MepR, a Repressor of the Staphylococcus aureus <i>mepA</i> Multidrug Efflux Pump Gene. <i>Journal of Bacteriology</i> , 2013, 195, 3651-3662.	2.2	18
85	Benzocyclohexane oxide derivatives and neolignans from Piper betle inhibit efflux-related resistance in Staphylococcus aureus. <i>RSC Advances</i> , 2016, 6, 43518-43525.	3.6	17
86	Topoisomerase Mutations in Fluoroquinolone-Resistant and Methicillin-Susceptible and -Resistant Clinical Isolates of Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 197-198.	3.2	16
87	Antibacterial Sesquiterpenoid Derivatives from Ferula ferulaeoides. <i>Planta Medica</i> , 2013, 79, 701-706.	1.3	16
88	In silico genetic correlations of multidrug efflux pump gene expression in Staphylococcus aureus. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 222-229.	2.5	14
89	The racemic approach in the evaluation of the enantiomeric NorA efflux pump inhibition activity of 2-phenylquinoline derivatives. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 182-189.	2.8	14
90	Treatment strategies for infective endocarditis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 345-360.	1.8	13

#	ARTICLE	IF	CITATIONS
91	Clonal relatedness is a predictor of spontaneous multidrug efflux pump gene overexpression in <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 464-470.	2.5	12
92	Teicoplanin pharmacodynamics in reference to the accessory gene regulator ( <i>agr</i> ) in <i>Staphylococcus aureus</i> using an in vitro pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1099-1102.	3.0	9
93	Evaluation of Daptomycin Non-Susceptible <i>Staphylococcus aureus</i> for Stability, Population Profiles, <i>mprF</i> Mutations, and Daptomycin Activity. <i>Infectious Diseases and Therapy</i> , 2013, 2, 187-200.	4.0	9
94	Modulation of the Drug Resistance by <i>Platonia insignis</i> Mart. Extract, Ethyl Acetate Fraction and Morelloflavone/Volkensiflavone (Biflavonoids) in <i>Staphylococcus aureus</i> Strains Overexpressing Efflux Pump Genes. <i>Current Drug Metabolism</i> , 2021, 22, 114-122.	1.2	9
95	Mutations within the <i>mepA</i> Operator Affect Binding of the MepR Regulatory Protein and Its Induction by MepA Substrates in <i>Staphylococcus aureus</i> . <i>Journal of Bacteriology</i> , 2015, 197, 1104-1114.	2.2	8
96	Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of <i>Staphylococcus</i> Species: Are the Susceptibility Breakpoints Too High?. <i>Clinical Infectious Diseases</i> , 2003, 37, 1392-1395.	5.8	7
97	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 43-55.	1.1	6
98	Efavirenz-Associated Urinary Matrix Stone—A Rare Presentation. <i>American Journal of the Medical Sciences</i> , 2016, 351, 213-214.	1.1	5
99	Fluoroquinolone Resistance in Bacteria. , 2009, , 195-205.		3
100	Fluoroquinolone Resistance in Bacteria. , 2017, , 245-263.		3
101	Role of Multidrug Efflux Pumps in Gram-Positive Bacteria. , 2014, , 275-285.		1